

TOP 5 HIGHLIGHTS FROM ELCC 2026



TOP Study • NCT04695925 • Phase 3

The combination of osimertinib (Tagrisso) and platinum-based doublet chemotherapy led to a significant improvement in progression-free survival vs osimertinib alone in patients with *EGFR*-mutant advanced non-small cell lung cancer harboring concurrent *TP53* mutations.



FLAURA2 • NCT04035486 • Phase 3 • Exploratory Analysis

Chemotherapy rechallenge proved to be common after disease progression on frontline osimertinib (Tagrisso) plus platinum and pemetrexed in patients with *EGFR*-mutated advanced non-small cell lung cancer, potentially because of a long chemotherapy-free interval, according to data from an exploratory analysis of the phase 3 FLAURA2 trial.



HS-10241-102 • NCT04695925 • Phase 3

The combination of dalmelitinib and aumolertinib demonstrated clinically meaningful and durable activity in patients with *EGFR*-mutant and *MET*-amplified advanced non-small cell lung cancer and manageable toxicity.



OptiTROP-Lung03 • NCT05631262 • Phase 2 • OS Analysis

The TROP2-directed antibody-drug conjugate sacituzumab tirumotecan displayed a significant overall survival (OS) benefit compared with docetaxel in patients with pretreated *EGFR*-mutated non-small cell lung cancer.



NorthStar • NCT03410043 • Phase 2 • Secondary Analysis

The addition of local consolidative therapy to osimertinib (Tagrisso) significantly prolonged progression-free survival compared with osimertinib monotherapy in patients with *EGFR*-mutated non-small cell lung cancer. Moreover, consolidative radiotherapy led to excellent local control rates, with disease recurrence primarily occurring outside of the radiotherapy field at new distant metastatic sites.